Molecular Oncology

The ARUP Molecular Oncology Laboratory offers a broad menu of testing and consultative services in oncology. Testing is designed to aid the physician in answering important clinical questions in the areas of screening, prognosis, treatment, and monitoring. An active research program in the ARUP Institute for Clinical and Experimental Pathology® is committed to developing molecular technologies that will ensure continued quality of clinical testing in the rapidly progressing field of molecular pathology.
  • Medical Director, Hematopathology and Special Genetics
    Dr. Agarwal is an associate professor of pathology at the University of Utah School of Medicine. She received her MD at Delhi University in India and was a postdoctoral research scholar at the University of Iowa. She served as a pathology resident, a hematopathology fellow, and a molecular genetics pathology fellow at the University of Utah School of Medicine. Dr. Agarwal is board certified in hematopathology, anatomic pathology, and clinical pathology. She is also a member of several professional societies, including the College of American Pathologists and the American Society for Clinical Pathology. Dr. Agarwal’s research interests include red-cell enzymopathies, hemoglobinopathies, and molecular hematopathology.
  • Medical Director, Molecular Oncology
    Dr. Bernard is an associate professor of anatomic pathology at the University of Utah School of Medicine. He received his MD from and completed his postdoctoral training at the University of Utah and is certified in clinical pathology by the American Board of Pathology. Dr. Bernard’s laboratory at the Huntsman Cancer Center utilizes comprehensive genomic analyses to identify and translate biomarkers into clinical care for cancer patients. His work in gene expression classification of breast cancer led to the development of PAM50 (Prosigna), an FDA-approved diagnostic offered worldwide. His current research interests include using circulating cancer biomarkers for monitoring and early detection, as well as translating newly discovered cancer alterations to large nucleic acid-based panels for personalized treatment in advanced disease.
  • Co-Division Chief, Anatomic and Molecular Oncologic Pathology
    Medical Director, Biocomputing
    Dr. Bronner is a Carl R. Kjeldsberg presidential endowed professor of pathology at the University of Utah School of Medicine. Dr. Bronner received her MD from the University of Pennsylvania and completed her pathology residency training and chief residency at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bronner’s honors include her election as president of the GI Pathology Society, election as council member of the United States and Canadian Academy of Pathology, and, in 2005, the award of the Arthur Purdy Stout Prize, recognizing her work as a surgical pathologist under the age of 45 whose research publications have had a major impact on diagnostic pathology. Dr. Bronner is an editorial journal board member for Human Pathology and Modern Pathology. She has served as an investigator on numerous NIH and foundation grants over the course of her career and has published more than 100 peer-reviewed articles and numerous book chapters.
  • Medical Director, Molecular Oncology
    Dr. Deftereos is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Bari Aldo Moro in Italy. Prior to his pathology training, Dr. Deftereos completed a research fellowship focusing on HPV and gynecological malignancies at the University of Washington in Seattle, Washington. He then completed a residency in anatomic and clinical pathology at Allegheny General Hospital in Pittsburgh, Pennsylvania, followed by consecutive clinical fellowships in cytopathology and molecular genetic pathology at the University of Washington. Dr. Deftereos is board certified in anatomic pathology, clinical pathology, cytopathology, and molecular genetic pathology, and provides service in the areas of molecular oncology and cytopathology. His research interests include epigenetics of solid tumors and minimally invasive precision diagnostics, with emphasis on the use of molecular testing in cytopathology of solid tumors.
  • Medical Director, Molecular Oncology
    Dr. Furtado is an assistant professor of pathology at the University of Utah School of Medicine. She completed her residency in anatomic and clinical pathology at the University of Utah and ARUP Laboratories, where she was chief resident, and her molecular genetic pathology fellowship at the University of Michigan. Prior to joining ARUP as a medical director, Dr. Furtado co-founded the Division of Genomic and Molecular Pathology at the University of Chicago, where she worked as an assistant professor of pathology and was the co-director of the University of Chicago Clinical Genomics and Molecular Diagnostics Laboratories. Dr. Furtado’s research interests include genomic diagnostics in solid tumors and molecular diagnostic methods in oncology.
  • Medical Director, Surgical Pathology and Molecular Oncology
    Dr. Grossmann received a BS in zoology at the College of Idaho and a PhD and MD from the Oregon Health Sciences University, where she studied tyrosine kinase substrate specificity with Brian J. Druker, MD. Dr. Grossmann completed both a residency in anatomic pathology and a research fellowship in molecular medicine at the University of Utah. Her postdoctoral work in the laboratory of Dean Y. Li, MD, PhD, focused on the role of small GTPases in melanoma invasion and metastasis. Most recently, Dr. Grossmann completed a fellowship in molecular genetic pathology at ARUP Laboratories. Her primary subspecialty interests are sarcoma pathology and molecular oncology. Her research interests include mechanisms of tumorgenesis, metastasis, and the development of targeted therapies for cancer treatment.
  • Medical Director, Molecular Hematopathology
    Medical Director, Hematopathology
    Dr. Kelley is an associate professor in the Department of Pathology at the University of Utah. He received his MS in immunology and microbiology and his MD from Ohio State University, and completed his residency in anatomic and clinical pathology and fellowship training in hematopathology at the Cleveland Clinic. He is board certified in anatomic and clinical pathology by the American Board of Pathology, with subspecialty certification in hematology. His research interests include the identification of novel diagnostic and prognostic biomarkers in leukemia and lymphoma.
  • Medical Director, Molecular Genetics and Genomics
    Medical Director, Pharmacogenomics
    Dr. Lyon is a professor of pathology at the University of Utah School of Medicine. She received her PhD in medical genetics from the University of Alabama at Birmingham and completed an ABMG fellowship in clinical molecular genetics at the University of Utah. Dr. Lyon’s responsibilities include validating methods for mutation detection under CLIA requirements, implementing them into clinical testing, and interpreting genetic/genomic results in a clinical context. She participated in the ACMG/AMP/CAP Standards and Guidelines for the Interpretation of Sequence Variants and served as president of the Association for Molecular Pathology in 2014.
  • Section Chief, Molecular Genetics and Genomics, ARUP Laboratories
    Professor of Pathology, University of Utah School of Medicine
    Dr. Mao is a professor of pathology and co-director of the Clinical Molecular Genetics Fellowship Program at the University of Utah School of Medicine. She received her MD from Capital University of Medicine in Beijing, China and her MS in molecular pathology from Beijing Union Medical College. She is board certified by the American Board of Medical Genetics, with a subspecialty in clinical molecular genetics, and certified with the New York State Department of Health, with a subspecialty in genetic testing. She is a member of several professional societies, including American College of Medical Genetics and Genomics, Association for Molecular Pathology, and American Society of Human Genetics. Her research interests include the genotype-phenotype correlations in inborn errors of metabolism and genetic diseases in the RAS/MAPK pathway; she is also involved with implementing next-generation sequencing techniques into molecular diagnostics.
  • Medical Director, Solid Tumor Molecular Diagnostics
    Dr. Matynia is an assistant professor of pathology at the University of Utah School of Medicine. She received her MD from the Jagiellonian University in Kraków, Poland, and completed her residency in pathology, as well as fellowships in hematopathology and molecular genetic pathology, at the University of Utah and ARUP Laboratories. Dr. Matynia is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty certification in hematology and molecular genetic pathology. Her academic interests include molecular diagnostics of hematolymphoid and solid tumor malignancies.

Pages